Consolidation Sintilimab After Concurrent Chemoradiation in Patients With Unresectable Stage III NSCLC (CONSIST)

Clinical Trial ID NCT03884192

Rank	Title	Journal	Year	PubWeight™‹?›
1	Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer.	J Clin Oncol	2010	5.99
2	Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.	Lancet Oncol	2015	4.63
3	Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04.	J Clin Oncol	2015	2.98
4	Is consolidation chemotherapy after concurrent chemo-radiotherapy beneficial for patients with locally advanced non-small-cell lung cancer? A pooled analysis of the literature.	J Thorac Oncol	2013	2.33
5	Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.	J Natl Compr Canc Netw	2017	0.99
6	Therapeutic management options for stage III non-small cell lung cancer.	World J Clin Oncol	2017	0.84
7	Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.	N Engl J Med	2017	0.75